Beovu

(Brolucizumab)

Beovu

Drug updated on 11/14/2023

Dosage FormInjection (intravitreal: 6 mg/0.05 mL)
Drug ClassHuman vascular endothelial growth factor inhibitors
Ongoing and Completed StudiesClinicalTrials.gov

Indication

  • For the treatment of Neovascular (Wet) Age-Related Macular Degeneration (AMD).
  • For the treatment of diabetic macular edema (DME).